Assay Blocking Blog camp elisa cDNA corticosterone elisa Elisa hama antibodies ldh assay kit mobp antibody Monoclonal Pcr pge2 elisa plc gamma 2 tbars assay kit tdgf1 upp1 Vector
Comparison of SpO 2 and heart rate values on Apple Watch and conventional commercial oximeters devices in patients with lung disease
Lung ailments have excessive mortality and morbidity, with an vital affect on high quality of life. Hypoxemic sufferers are suggested to make use of oxygen remedy to extend their survival, however excessive oxygen saturation (SpO2) ranges also can have destructive results. Pulse oximeters are the commonest option to assess oxygen ranges and information medical therapy.
This research goals to evaluate whether or not wearable gadgets can present exact SpO2 measurements when in comparison with industrial pulse oximeters. It is a cross-section research with 100 sufferers with power obstructive pulmonary illness and interstitial lung illness from an outpatient pneumology clinic.
SpO2 and coronary heart fee information had been collected with an Apple Watch Collection 6 (Apple) and in comparison with two industrial pulse oximeters. The Bland-Altman technique and interclass correlation coefficient had been used to match their values.
We noticed sturdy constructive correlations between the Apple Watch system and industrial oximeters when evaluating coronary heart fee measurements (r = 0.995, p < 0.001) and oximetry measurements (r = 0.81, p < 0.001).
There was no statistical distinction within the analysis of pores and skin shade, wrist circumference, presence of wrist hair, and enamel nail for SpO2 and coronary heart fee measurements in Apple Watch or industrial oximeter gadgets (p > 0.05). Apple Watch 6 is a dependable option to get hold of coronary heart fee and SpO2 in sufferers with lung ailments in a managed atmosphere.
Genetic evaluation by focused next-generation sequencing and novel variation identification of maple syrup urine illness in Chinese language Han inhabitants
Maple syrup urine illness (MSUD) is a uncommon autosomal recessive dysfunction that impacts the degradation of branched chain amino acids (BCAAs). Only some circumstances of MSUD have been documented in Mainland China. On this report, eight sufferers (Four females and Four males) with MSUD from eight unrelated Chinese language Han households had been identified on the age of 6 days to Four months.
All of the coding areas and exon/intron boundaries of BCKDHA, BCDKHB, DBT and DLD genes had been analyzed by focused NGS within the eight MSUD pedigrees. Focused NGS revealed 2 pedigrees with MSUD Ia, 5 pedigrees with Ib, 1 pedigree with MSUD II. Completely, 13 variants had been detected, together with 2 variants (p.Ala216Val and p.Gly281Arg) in BCKDHA gene, 10 variants (p.Gly95Ala, p.Ser171Professional, p.Phe175Leu, p.Arg183Trp, p.Lys222Thr, p.Arg285Ter, p.Arg111Ter, p.S184Pfs*46, p.Arg170Cys, p.I160Ffs*25) in BCKDHB gene, 1 variant (p.Arg431Ter) in DBT gene.
As well as, Four beforehand unidentified variants (p.Gly281Arg in BCKDHA gene, p.Ser171Professional, p.Gly95Ala and p.Lys222Thr in BCKDHB gene) had been recognized. NGS plus Sanger sequencing detection is efficient and correct for gene analysis. Computational structural modeling indicated that these novel variations in all probability have an effect on structural stability and regarded as possible pathogenic variants.
Elements related to the distinction between the incidence and case-fatality ratio of coronavirus illness 2019 by nation
Coronavirus illness (COVID-19) has been spreading everywhere in the world; nonetheless, its incidence and case-fatality ratio differ enormously between nations and between continents. We investigated components related to worldwide variation in COVID-19 incidence and case-fatality ratio (CFR) throughout 107 northern hemisphere nations, utilizing publicly obtainable COVID-19 end result information as of 14 September 2020.
We included country-specific geographic, demographic, socio-economic options, world well being safety index (GHSI), healthcare capability, and main well being conduct indexes in multivariate fashions to clarify this variation.
A number of linear regression highlighted that incidence was related to ethnic area (p < 0.05), world well being safety index 4 (GHSI4) (beta coefficient [β] 0.50, 95% Confidence Interval [CI] 0.14-0.87), inhabitants density (β 0.35, 95% CI 0.10-0.60), and water security degree (β 0.51, 95% CI 0.19-0.84).
The CFR was related to ethnic area (p < 0.05), GHSI4 (β 0.53, 95% CI 0.14-0.92), proportion of inhabitants over 65 (β 0.71, 95% CI 0.19-1.24), worldwide tourism receipt degree (β – 0.23, 95% CI – 0.43 to – 0.03), and the variety of physicians (β – 0.37, 95% CI – 0.69 to – 0.06). Ethnic area was probably the most influential issue for each COVID-19 incidence (partial [Formula: see text] = 0.545) and CFR (partial [Formula: see text] = 0.372), even after adjusting for numerous confounding components.
Excessive ranges of osteoprotegerin are related to coronary artery calcification in sufferers suspected of a power coronary syndrome
Plasma osteoprotegerin (OPG) and vascular easy muscle cell (VSMC) derived extracellular vesicles (EVs) are vital regulators within the means of vascular calcification (VC). In inhabitants research, excessive ranges of OPG are related to occasions.
In animal research, nonetheless, excessive OPG ranges end in discount of VC. VSMC-derived EVs are assumed to be accountable for OPG transport and VC however this position has not been studied. For this, we investigated the affiliation between OPG in plasma and circulating EVs with coronary artery calcium (CAC) as surrogate for VC in symptomatic sufferers.
We retrospectively assessed 742 sufferers present process myocardial perfusion imaging (MPI). CAC scores had been decided on the MPI-CT pictures utilizing a beforehand developed automated algorithm. Ranges of OPG had been quantified in plasma and two EV-subpopulations (LDL and TEX), utilizing an electrochemiluminescence immunoassay.
Circulating ranges of OPG had been independently related to CAC scores in plasma; OR 1.39 (95% CI 1.17-1.65), and each EV populations; EV-LDL; OR 1.51 (95% CI 1.27-1.80) and EV-TEX; OR 1.21 (95% CI 1.02-1.42). Excessive ranges of OPG in plasma had been independently related to CAC scores on this symptomatic affected person cohort. Excessive ranges of EV-derived OPG confirmed the identical constructive affiliation with CAC scores, suggesting that EV-derived OPG mirrors the identical pathophysiological course of as plasma OPG.
Circadian Clock-Managed Checkpoints within the Pathogenesis of Advanced Illness
The circadian clock coordinates physiology, metabolism, and conduct with the 24-h cycles of environmental mild. Elementary mechanisms of how the circadian clock regulates organ physiology and metabolism have been elucidated at a speedy pace prior to now twenty years.
Right here we evaluate circadian networks in additional than six organ techniques related to complicated illness, which cluster round metabolic problems, and search to suggest crucial regulatory molecules managed by the circadian clock (named clock-controlled checkpoints) within the pathogenesis of complicated illness.
These embrace clock-controlled checkpoints akin to circadian nuclear receptors in liver and muscle tissues, chemokines and adhesion molecules within the vasculature. Though the progress is encouraging, many gaps within the mechanisms stay unaddressed.
XKR4 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV658337 | ABM | 1.0 ug DNA | EUR 818.4 |
XKR8 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV627564 | ABM | 1.0 ug DNA | EUR 818.4 |
XKR7 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV658104 | ABM | 1.0 ug DNA | EUR 818.4 |
XKR4 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV658338 | ABM | 1.0 ug DNA | EUR 818.4 |
XKR8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV627560 | ABM | 1.0 ug DNA | EUR 818.4 |
XKR7 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV658100 | ABM | 1.0 ug DNA | EUR 818.4 |
XKR4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV658334 | ABM | 1.0 ug DNA | EUR 818.4 |
XKR8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV627561 | ABM | 1.0 ug DNA | EUR 888 |
XKR8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV627562 | ABM | 1.0 ug DNA | EUR 888 |
XKR7 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV658101 | ABM | 1.0 ug DNA | EUR 888 |
XKR7 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV658102 | ABM | 1.0 ug DNA | EUR 888 |
XKR4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV658335 | ABM | 1.0 ug DNA | EUR 888 |
XKR4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV658336 | ABM | 1.0 ug DNA | EUR 888 |
XKRX Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV653833 | ABM | 1.0 ug DNA | EUR 818.4 |
XKRX Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV653837 | ABM | 1.0 ug DNA | EUR 818.4 |
Xkr5 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL701731 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr9 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL701732 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr4 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL701484 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr7 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL701601 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr8 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL701608 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKRX Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV653838 | ABM | 1.0 ug DNA | EUR 818.4 |
XKR8 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL300426 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKR5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL300427 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKR4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL300428 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKR3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL300429 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr4 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL515697 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKR9 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL308348 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKR7 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL308349 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr5 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL510508 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr9 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL508586 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr8 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL508614 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr7 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL506817 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKRYP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV789965 | ABM | 1.0 ug DNA | Ask for price |
XKRYP1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV789969 | ABM | 1.0 ug DNA | Ask for price |
XKRYP2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV789971 | ABM | 1.0 ug DNA | Ask for price |
XKRYP2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV789975 | ABM | 1.0 ug DNA | Ask for price |
XKRYP3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV789977 | ABM | 1.0 ug DNA | Ask for price |
XKRYP3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV789981 | ABM | 1.0 ug DNA | Ask for price |
XKRYP4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV789983 | ABM | 1.0 ug DNA | Ask for price |
XKRYP4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV789987 | ABM | 1.0 ug DNA | Ask for price |
XKRYP5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV789989 | ABM | 1.0 ug DNA | Ask for price |
XKRYP5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV789993 | ABM | 1.0 ug DNA | Ask for price |
XKRYP6 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV789995 | ABM | 1.0 ug DNA | Ask for price |
XKRYP6 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV789999 | ABM | 1.0 ug DNA | Ask for price |
XKRYP1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV789970 | ABM | 1.0 ug DNA | Ask for price |
XKRYP2 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV789976 | ABM | 1.0 ug DNA | Ask for price |
XKRYP3 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV789982 | ABM | 1.0 ug DNA | Ask for price |
XKRYP4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV789988 | ABM | 1.0 ug DNA | Ask for price |
XKRYP5 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV789994 | ABM | 1.0 ug DNA | Ask for price |
XKRYP6 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV790000 | ABM | 1.0 ug DNA | Ask for price |
XKRX Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV653834 | ABM | 1.0 ug DNA | EUR 818.4 |
XKRX Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV653835 | ABM | 1.0 ug DNA | EUR 888 |
XKRX Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV653836 | ABM | 1.0 ug DNA | EUR 888 |
XKRYP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV789966 | ABM | 1.0 ug DNA | Ask for price |
XKRYP2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV789972 | ABM | 1.0 ug DNA | Ask for price |
XKRYP3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV789978 | ABM | 1.0 ug DNA | Ask for price |
XKRYP4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV789984 | ABM | 1.0 ug DNA | Ask for price |
XKRYP5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV789990 | ABM | 1.0 ug DNA | Ask for price |
XKRYP6 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV789996 | ABM | 1.0 ug DNA | Ask for price |
XKRYP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV789967 | ABM | 1.0 ug DNA | Ask for price |
XKRYP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV789968 | ABM | 1.0 ug DNA | Ask for price |
XKRYP2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV789973 | ABM | 1.0 ug DNA | Ask for price |
XKRYP2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV789974 | ABM | 1.0 ug DNA | Ask for price |
XKRYP3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV789979 | ABM | 1.0 ug DNA | Ask for price |
XKRYP3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV789980 | ABM | 1.0 ug DNA | Ask for price |
XKRYP4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV789985 | ABM | 1.0 ug DNA | Ask for price |
XKRYP4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV789986 | ABM | 1.0 ug DNA | Ask for price |
XKRYP5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV789991 | ABM | 1.0 ug DNA | Ask for price |
XKRYP5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV789992 | ABM | 1.0 ug DNA | Ask for price |
XKRYP6 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV789997 | ABM | 1.0 ug DNA | Ask for price |
XKRYP6 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV789998 | ABM | 1.0 ug DNA | Ask for price |
Xkrx - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL701733 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKRX - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL300425 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKRY - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL316849 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkrx - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL514262 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
XKRY2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL318395 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Xkr6 ORF Vector (Rat) (pORF) |
|||
| ORF079204 | ABM | 1.0 ug DNA | EUR 607.2 |
XKR6 ORF Vector (Human) (pORF) |
|||
| ORF011641 | ABM | 1.0 ug DNA | EUR 114 |
Xkr6 ORF Vector (Mouse) (pORF) |
|||
| ORF061944 | ABM | 1.0 ug DNA | EUR 607.2 |
CD Lentiviral Vector |
|||
| LV678 | ABM | 10 μg | EUR 950 |
XKR6 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV316816 | ABM | 500 ng | EUR 723.6 |
XKR6 Protein Vector (Rat) (pPB-C-His) |
|||
| PV316814 | ABM | 500 ng | EUR 723.6 |
XKR6 Protein Vector (Rat) (pPB-N-His) |
|||
| PV316815 | ABM | 500 ng | EUR 723.6 |
XKR6 Protein Vector (Rat) (pPM-C-His) |
|||
| PV316817 | ABM | 500 ng | EUR 723.6 |
XKR6 Protein Vector (Human) (pPM-C-HA) |
|||
| PV046563 | ABM | 500 ng | EUR 394.8 |
XKR6 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV247776 | ABM | 500 ng | EUR 723.6 |
XKR6 Protein Vector (Human) (pPB-C-His) |
|||
| PV046561 | ABM | 500 ng | EUR 394.8 |
XKR6 Protein Vector (Human) (pPB-N-His) |
|||
| PV046562 | ABM | 500 ng | EUR 394.8 |
XKR6 Protein Vector (Human) (pPM-C-His) |
|||
| PV046564 | ABM | 500 ng | EUR 394.8 |
XKR6 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV247774 | ABM | 500 ng | EUR 723.6 |
XKR6 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV247775 | ABM | 500 ng | EUR 723.6 |
XKR6 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV247777 | ABM | 500 ng | EUR 723.6 |
dCas9-KRAB Lentiviral Vector |
|||
| K203 | ABM | 10 ug | EUR 165 |
|
Description: N/A |
|||
Cas9 Nickase Lentiviral Vector |
|||
| K005 | ABM | 10 ug | EUR 135 |
|
Description: N/A |
|||
Cas9 Nuclease Lentiviral Vector |
|||
| K002 | ABM | 10 ug | EUR 135 |
|
Description: N/A |
|||
Xkr6 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL701552V | Origene Technologies GmbH | 500 ul each | Ask for price |
XKR6 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL318316V | Origene Technologies GmbH | 500 ul each | Ask for price |
Xkr6 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL517341V | Origene Technologies GmbH | 500 ul each | Ask for price |
dCas9-TET1CD Lentiviral Vector |
|||
| K096 | ABM | 10 µg, Titer: N/A | EUR 395 |
|
Description: N/A |
|||
dCas9-DNMT3A Lentiviral Vector |
|||
| K091 | ABM | 10 µg, Titer: N/A | EUR 395 |
|
Description: N/A |
|||
Green Kit. Baculovirus GFP vector. |
|||
| K20 | AB Vector LLC | 1 Kit | EUR 695 |
|
Description: Protein expression |
|||
ProGreen. Baculovirus GFP marker vector. |
|||
| A1 | AB Vector LLC | 25 ul | EUR 420 |
|
Description: Protein expression |
|||
pVL1393. General baculovirus plasmid vector. |
|||
| B1 | AB Vector LLC | 50 ul | EUR 340 |
|
Description: Protein expression |
|||
Cas9 Double Mutant Lentiviral Vector |
|||
| K012 | ABM | 10 ug | EUR 395 |
|
Description: N/A |
|||
Luciferase-mCherry Lentiviral Vector (CMV) |
|||
| LV010138 | ABM | 1.0 μg | EUR 230 |
ESR1 Lentiviral Vector (Human) (pLenti-II) |
|||
| LV010008 | ABM | 1.0 ug DNA | EUR 379.2 |
ProEasy. Vector for easy construction of recombinant baculoviruses. |
|||
| A10S | AB Vector LLC | 25 ul | EUR 695 |
|
Description: Protein expression |
|||
pLenti-GFP Lentiviral Control Vector |
|||
| LTV-400 | Cell Biolabs | 100 µL | EUR 500 |
pLenti-GFP Lentiviral Control Vector |
|||
| MBS168202-01mL | MyBiosource | 0.1mL | EUR 660 |
pLenti-GFP Lentiviral Control Vector |
|||
| MBS168202-5x01mL | MyBiosource | 5x0.1mL | EUR 2795 |
pAcAB3. Baculovirus plasmid vector for expression of up to 3 proteins. |
|||
| B2 | AB Vector LLC | 50 ul | EUR 420 |
|
Description: Protein expression |
|||
pSMPUW-Neo Lentiviral Expression Vector |
|||
| VPK-213 | Cell Biolabs | 10 µg | EUR 505 |
pLenti-MCS Lentiviral Expression Vector |
|||
| LV000 | ALSTEM | 10 µg | EUR 416.5 |
pSMPUW-Neo Lentiviral Expression Vector |
|||
| MBS169522-001mg | MyBiosource | 0.01mg | EUR 665 |
pSMPUW-Neo Lentiviral Expression Vector |
|||
| MBS169522-5x001mg | MyBiosource | 5x0.01mg | EUR 2825 |
pAB-bee. Baculovirus plasmid vector for secreted and transmembrane proteins. |
|||
| B3 | AB Vector LLC | 50 ul | EUR 495 |
|
Description: Protein expression |
|||
pSMPUW-Puro Lentiviral Expression Vector |
|||
| VPK-212 | Cell Biolabs | 10 µg | EUR 505 |
pSMPUW-Puro Lentiviral Expression Vector |
|||
| MBS169521-001mg | MyBiosource | 0.01mg | EUR 665 |
pSMPUW-Puro Lentiviral Expression Vector |
|||
| MBS169521-5x001mg | MyBiosource | 5x0.01mg | EUR 2825 |
pSMPUW-Hygro Lentiviral Expression Vector |
|||
| VPK-214 | Cell Biolabs | 10 µg | EUR 505 |
pSMPUW-MNDnLacZ Lentiviral Control Vector |
|||
| LTV-402 | Cell Biolabs | 10 µg | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pSMPUW-Hygro Lentiviral Expression Vector |
|||
| MBS169523-001mg | MyBiosource | 0.01mg | EUR 665 |
pSMPUW-Hygro Lentiviral Expression Vector |
|||
| MBS169523-5x001mg | MyBiosource | 5x0.01mg | EUR 2825 |
ProFold-PDI. Baculovirus chaperone vector for expression of cysteine-rich proteins. |
|||
| A7 | AB Vector LLC | 25 ul | EUR 830 |
|
Description: Protein expression |
|||
TH Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699655 | ABM | 1.0 ug DNA | EUR 818.4 |
TH Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699659 | ABM | 1.0 ug DNA | EUR 818.4 |
SI Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV694363 | ABM | 1.0 ug DNA | EUR 3415.2 |
SI Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV694367 | ABM | 1.0 ug DNA | EUR 3415.2 |
MB Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV694681 | ABM | 1.0 ug DNA | EUR 616.8 |
MB Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV694685 | ABM | 1.0 ug DNA | EUR 616.8 |
T Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV639319 | ABM | 1.0 ug DNA | EUR 818.4 |
T Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV639323 | ABM | 1.0 ug DNA | EUR 818.4 |
F7 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV666001 | ABM | 1.0 ug DNA | EUR 818.4 |
F7 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV666005 | ABM | 1.0 ug DNA | EUR 818.4 |
FH Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV666085 | ABM | 1.0 ug DNA | EUR 818.4 |
FH Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV666089 | ABM | 1.0 ug DNA | EUR 818.4 |
F9 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV667969 | ABM | 1.0 ug DNA | EUR 818.4 |
F9 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV667973 | ABM | 1.0 ug DNA | EUR 818.4 |
C6 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV673381 | ABM | 1.0 ug DNA | EUR 1626 |
Future research ought to deal with devising time-dependent methods for drug supply and engagement in well-characterized organs such because the liver, and elucidating elementary circadian biology in to date much less characterised organ techniques, together with the center, blood, peripheral neurons, and reproductive techniques.
